Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report issued on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research note on Wednesday, May 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of Hold and an average price target of $5.67.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO opened at $0.40 on Friday. The firm has a market capitalization of $83.27 million, a PE ratio of -0.22 and a beta of 1.24. The business has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.61. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. During the same quarter in the prior year, the company earned $0.12 earnings per share. As a group, research analysts anticipate that Sangamo Therapeutics will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Large investors have recently modified their holdings of the stock. Wasatch Advisors LP grew its stake in Sangamo Therapeutics by 62.4% during the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after purchasing an additional 7,734,400 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sangamo Therapeutics during the 1st quarter valued at approximately $331,000. Golden State Equity Partners grew its stake in Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in Sangamo Therapeutics by 72.4% during the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.